{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:01:03Z","timestamp":1772049663396,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.vaccine.2014.04.052","type":"journal-article","created":{"date-parts":[[2014,5,23]],"date-time":"2014-05-23T05:30:13Z","timestamp":1400823013000},"page":"4220-4227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines"],"prefix":"10.1016","volume":"32","author":[{"given":"Olubukola T.","family":"Idoko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seline N.","family":"Okolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Plikaytis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adebayo","family":"Akinsola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta","family":"Viviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Carlone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Findlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Elie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Pierre","family":"Preziosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Kampmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.04.052_bib0005","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1365-3156.2006.01639.x","article-title":"Editorial: 100 years of epidemic meningitis in West Africa \u2013 has anything changed?","volume":"11","author":"Greenwood","year":"2006","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1473-3099(12)70168-8","article-title":"Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data","volume":"12","author":"Novak","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0015","first-page":"129","article-title":"[Ist note concerning the activity of a single dose of sulfamethoxypyridazine by intramuscular route in the treatment of meningococcal cerebrospinal meningitis]","volume":"21","author":"Lapeyssonnie","year":"1961","journal-title":"Med Trop (Mars)"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0035-9203(99)90106-2","article-title":"Manson lecture. Meningococcal meningitis in Africa","volume":"93","author":"Greenwood","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0163-4453(98)80002-9","article-title":"Spread of Neisseria meningitidis group A clone III-I meningitis epidemic into Zambia","volume":"36","author":"Luo","year":"1998","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0030","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0035","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0035-9203(02)90089-1","article-title":"Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa","volume":"96","author":"Molesworth","year":"2002","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0040","first-page":"745","article-title":"Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines","volume":"81","author":"Robbins","year":"2003","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0045","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/infdis\/166.2.359","article-title":"Epidemic meningococcal disease in Nairobi, Kenya, 1989. The Kenya\/Centers for Disease Control (CDC) Meningitis Study Group","volume":"166","author":"Pinner","year":"1992","journal-title":"J Infect Dis"},{"issue":"9911","key":"10.1016\/j.vaccine.2014.04.052_bib0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0055","doi-asserted-by":"crossref","DOI":"10.3810\/pgm.2006.06.1640","article-title":"The new meningococcal conjugate vaccine. A profile of its safety, efficacy, and indications for use","volume":"119","author":"Pichichero","year":"2006","journal-title":"Postgrad Med"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0060","first-page":"217","article-title":"Presentation and outcome of sporadic acute bacterial meningitis in children in the African meningitis belt: recent experience from northern Nigeria highlighting emergent factors in outcome","volume":"14","author":"Akpede","year":"1995","journal-title":"West Afr J Med"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0065","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0092-1157(82)80010-3","article-title":"Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W, 135, clinical and serological evaluation","volume":"10","author":"Armand","year":"1982","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0070","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","article-title":"A review of vaccine research and development: meningococcal disease","volume":"24","author":"Girard","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0075","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJM197709292971302","article-title":"Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age","volume":"297","author":"Peltola","year":"1977","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2014.04.052_bib0080","doi-asserted-by":"crossref","first-page":"A108","DOI":"10.1016\/j.vaccine.2007.05.001","article-title":"The promise of conjugate vaccines for Africa","volume":"25","author":"Kieny","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0085","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/15513810701209538","article-title":"Prevention of meningococcal disease","volume":"25","author":"Woodard","year":"2006","journal-title":"Fetal Pediatr Pathol"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0090","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.2223\/JPED.1495","article-title":"Meningococcal conjugate vaccines: efficacy and new combinations","volume":"82","author":"Safadi","year":"2006","journal-title":"J Pediatr (Rio J)"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0095","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0140-6736(03)13494-0","article-title":"Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries","volume":"361","author":"Jodar","year":"2003","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2014.04.052_bib0100","doi-asserted-by":"crossref","first-page":"A97","DOI":"10.1016\/j.vaccine.2007.04.049","article-title":"The meningitis vaccine project","volume":"25","author":"LaForce","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0105","doi-asserted-by":"crossref","first-page":"e29116","DOI":"10.1371\/journal.pone.0029116","article-title":"Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS ONE"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2014.04.052_bib0110","doi-asserted-by":"crossref","first-page":"B46","DOI":"10.1016\/j.vaccine.2011.12.112","article-title":"Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010","volume":"30","author":"Ouandaogo","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.04.052_bib0115","doi-asserted-by":"crossref","first-page":"B40","DOI":"10.1016\/j.vaccine.2011.12.073","article-title":"Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience","volume":"30","author":"Djingarey","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0120","unstructured":"Immunization, Vaccines and Biologicals. Revolutionary meningitis vaccine breaks another barrier; first to gain approval to travel outside cold chain. WHO (Online) (cited 05 Dec 2013) available from www.who.int\/immunization\/newsroom\/menafrivac_20121114\/en\/."},{"key":"10.1016\/j.vaccine.2014.04.052_bib0125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2014.04.052_bib0130","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0135","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans","volume":"364","author":"Sow","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0140","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1086\/603552","article-title":"Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand","volume":"49","author":"Lennon","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0145","first-page":"275","article-title":"Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project","volume":"22","author":"Soriano-Gabarro","year":"2004","journal-title":"J Health Popul Nutr"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0150","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.vaccine.2008.11.092","article-title":"Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa","volume":"27","author":"Okoko","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0155","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1086\/344324","article-title":"Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom","volume":"186","author":"Borrow","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0160","doi-asserted-by":"crossref","first-page":"e2159","DOI":"10.1371\/journal.pone.0002159","article-title":"A phase II, randomized study on an investigational DTPw-HBV\/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana","volume":"3","author":"Hodgson","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0165","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/JCM.32.6.1475-1482.1994","article-title":"Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay","volume":"32","author":"Gheesling","year":"1994","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0170","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection \u2013 serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/CVI.00008-07","article-title":"Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7","volume":"14","author":"Norheim","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0180","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/infdis\/143.1.32","article-title":"Antibody response to capsular polysaccharides of groups A and C Neisseria meningitidis and Haemophilus influenzae type b during bacteremic disease","volume":"143","author":"Kayhty","year":"1981","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0185","first-page":"594","volume":"594","author":"Organization","year":"1976","journal-title":"Requirements for meningococcal polysaccharide vaccines"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0190","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/S0264-410X(01)00028-7","article-title":"Neonatal and early life vaccinology","volume":"19","author":"Siegrist","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0195","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1016\/j.vaccine.2011.04.068","article-title":"Mother\u2013infant vaccination with pneumococcal polysaccharide vaccine: persistence of maternal antibodies and responses of infants to vaccination","volume":"29","author":"Holmlund","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0200","first-page":"117","article-title":"Effect of passive immunity to tetanus in DTP vaccinated infants","volume":"16","author":"Sangpetchsong","year":"1985","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2014.04.052_bib0205","doi-asserted-by":"crossref","first-page":"A58","DOI":"10.1016\/j.vaccine.2007.04.042","article-title":"A new approach to the definition of seroconversion following vaccination in a population with high background antibody concentrations","volume":"25","author":"Chandramohan","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0210","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2014.04.052_bib0215","doi-asserted-by":"crossref","first-page":"A101","DOI":"10.1016\/j.vaccine.2007.04.050","article-title":"Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults","volume":"25","author":"Kshirsagar","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0220","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/IAI.6.5.651-656.1972","article-title":"Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3","volume":"6","author":"Robbins","year":"1972","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0225","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/IAI.13.6.1654-1662.1976","article-title":"Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide","volume":"13","author":"Vann","year":"1976","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0230","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1084\/jem.162.6.1837","article-title":"Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies","volume":"162","author":"Guirguis","year":"1985","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.04.052_bib0235","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/tmi.12125","article-title":"Meningococcal carriage in the African meningitis belt","volume":"18","author":"Ali","year":"2013","journal-title":"Trop Med Int Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14005908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14005908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T21:05:32Z","timestamp":1597871132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14005908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":47,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0264410X14005908"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}